FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
Blog|Videos|March 10, 2023
Invictus
Author(s)Richard M. Berlin, MD
"Under the bludgeonings of chance, My head is bloody, but unbowed."
Advertisement
Any Good Poem
Richard Berlin, MD, shares the poem "
Dr Berlin has been writing a poem about his experience of being a doctor every month for the past 25 years in Psychiatric Times™ in a column called “Poetry of the Times.” He is instructor in psychiatry, University of Massachusetts Medical School, Worcester, Massachusetts. His latest book is Freud on My Couch.
Advertisement
Related to this article
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.
There is a question older than medicine, and perhaps older than philosophy, that psychiatry has largely avoided: What makes us human?
APSARD is preparing US adult ADHD guidelines, delivering long-awaited screening, diagnosis, and treatment recommendations as experts discuss the upcoming release.
Review top pipeline updates from last week.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
2
The New, Impending Adult ADHD Guidelines
3
Reframing “Treatment-Resistant” as “Difficult-To-Treat”
4
Relief Is Not Free: A Case Study of Athlete Cannabis Use
5